TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31274775

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 µg/kg/min)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Milrinone (0.4 µg/kg/min)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 72

Group type: COMPARATOR
Intervention: Milrinone
Number of subjects: 72
Study: 28898204

Group type: EXPERIMENTAL
Intervention: Beraprost sodium (BPS) plus Aspirin (40 μg, tid and 100 mg, qd)
Number of subjects: 308

Group type: COMPARATOR
Intervention: Aspirin (100 mg, qd)
Number of subjects: 308
Study: 26135078

Group type: EXPERIMENTAL
Intervention: Handout directing to the ASSH web page on carpal tunnel syndrome in addition to standard care.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care during a traditional physician office visit.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Internet usage (not specified if treatment or control).
Number of subjects: 60
Study: 23636311

Group type: EXPERIMENTAL
Intervention: Motivational interviewing
Number of subjects: 74
Study: 21942317

Group type: EXPERIMENTAL
Intervention: Self-testing and evaluating learning before selecting passages to restudy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prompt questions without overt self-testing or evaluation
Number of subjects: 0

Group type: COMPARATOR
Intervention: No prompts, simply given the menu for selecting passages to restudy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-testing with idea-unit judgments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-testing without idea-unit judgments
Number of subjects: 0
Study: 19190927

Group type: EXPERIMENTAL
Intervention: Implanon
Number of subjects: 23

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 23
Study: 17902062

Group type: EXPERIMENTAL
Intervention: Potassium-magnesium-aspartate solution (Inzolen)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Potassium chloride
Number of subjects: 88
Study: 15331332

Group type: EXPERIMENTAL
Intervention: Penicillin V plus antioxidant vitamins (beta carotene, alpha tocopherol and ascorbic acid)
Number of subjects: 516

Group type: COMPARATOR
Intervention: Phenoxymethyl penicillin V
Number of subjects: 516
Study: 11332784

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 15
Study: 9325826

Group type: EXPERIMENTAL
Intervention: Hydrofibre dressing
Number of subjects: 44

Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 44
Study: 7950508

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (30 mg/day)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Prednisone (7.5 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 3604885

Group type: EXPERIMENTAL
Intervention: Sotalol (160 to 800 mg/day, median 323 mg, mean 386 mg)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 22
Study: 2293801

Group type: EXPERIMENTAL
Intervention: Educational program for children with asthma
Number of subjects: 253
Study: 236804

Group type: EXPERIMENTAL
Intervention: Metiamide 1 g daily by mouth
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31078325

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: EndoSequence root repair material (RRM)
Number of subjects: 243
Study: 28898283

Group type: EXPERIMENTAL
Intervention: HAP plus EUC
Number of subjects: 495

Group type: COMPARATOR
Intervention: EUC alone
Number of subjects: 495
Study: 25020104

Group type: EXPERIMENTAL
Intervention: Pistacia atlantica Var. mutica mouthwash
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (CHX) mouthwash
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 23562525

Group type: EXPERIMENTAL
Intervention: Zirconia (Zc)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Machined pure titanium (MPT)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cast and polished titanium (CPT)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Total cell count across all groups
Number of subjects: 6
Study: 21272413

Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplementation (15 mg/d)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: Zinc gluconate supplementation (30 mg/d)
Number of subjects: 387

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 387
Study: 18853107

Group type: COMPARATOR
Intervention: Venturi pump
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Peristaltic pump
Number of subjects: 49
Study: 17074331

Group type: EXPERIMENTAL
Intervention: FHA
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control
Number of subjects: 27
Study: 14749754

Group type: EXPERIMENTAL
Intervention: Fat-reduced, high-simple carbohydrate diet (SCHO)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Fat-reduced, high-complex carbohydrate diet (CCHO)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Normal-fat diet (control, CD)
Number of subjects: 46
Study: 11384788

Group type: EXPERIMENTAL
Intervention: Incentives to improve follow-up for tuberculosis therapy after release from jail
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Search strategies including phone calls, letters, and personal contacts
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Outreach efforts in shelters and drug/alcohol programs
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Outreach efforts in Latino community areas
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Primary English speakers
Number of subjects: 254

Group type: EXPERIMENTAL
Intervention: Subjects found back in jail
Number of subjects: 254
Study: 9400508

Group type: EXPERIMENTAL
Intervention: Doxorubicin-based adjuvant chemotherapy
Number of subjects: 1568
Study: 8121914

Group type: EXPERIMENTAL
Intervention: 32P with low-dose hydroxy-urea (500 mg/day) maintenance therapy
Number of subjects: 237

Group type: COMPARATOR
Intervention: 32P without hydroxy-urea maintenance therapy
Number of subjects: 237
Study: 3303287

Group type: EXPERIMENTAL
Intervention: Nicardipine 20 mg three times daily for 2 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nicardipine 20-40 mg three times daily during an open study in 30 patients
Number of subjects: 20
Study: 30489620

Group type: COMPARATOR
Intervention: Volatile induction and maintenance anesthesia (VIMA) with sevoflurane and nitrous oxide
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with remifentanil hydrochloride and propofol
Number of subjects: 80
Study: 28478399

Group type: EXPERIMENTAL
Intervention: hUC-MSC (2×10^8 cells)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: hUC-MSC
Number of subjects: 18

Group type: COMPARATOR
Intervention: hUC-MSC and Placebo
Number of subjects: 18
Study: 26588261

Group type: EXPERIMENTAL
Intervention: Morning exercise (8-10 a.m.)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Evening exercise (6-8 p.m.)
Number of subjects: 10
Study: 23563576

Group type: EXPERIMENTAL
Intervention: LCZ696 200 mg b.i.d.
Number of subjects: 8436

Group type: COMPARATOR
Intervention: Enalapril 10 mg b.i.d.
Number of subjects: 8436
Study: 21593649

Group type: EXPERIMENTAL
Intervention: Orafti Synergy1 (50 oligofructose:50 FOS) 0.4 g/dL
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Orafti Synergy1 (50 oligofructose:50 FOS) 0.8 g/dL
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: GOS:FOS (90:10) 0.8 g/dL
Number of subjects: 110

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 110

Group type: COMPARATOR
Intervention: Breast-fed group
Number of subjects: 110
Study: 17905788

Group type: EXPERIMENTAL
Intervention: Information Campaign (IC)
Number of subjects: 183

Group type: COMPARATOR
Intervention: No Information Campaign (no-IC)
Number of subjects: 183
Study: 16871715

Group type: EXPERIMENTAL
Intervention: Fractal lacunarity analysis using a hyperbola model function to approximate the lacunarity function with coefficients alpha, beta, and gamma.
Number of subjects: 0
Study: 12551829

Group type: EXPERIMENTAL
Intervention: Nadroparin (2,850 IU subcutaneously daily for 90 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Warfarin (1 mg orally daily for 90 days)
Number of subjects: 59
Study: 10589631

Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg/mL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg/mL
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ropivacaine 7.5 mg/mL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (Control group)
Number of subjects: 80
Study: 8724540

Group type: EXPERIMENTAL
Intervention: Gallium-67 SPECT
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CT and 67Ga SPECT
Number of subjects: 33
Study: 1912833

Group type: EXPERIMENTAL
Intervention: Adjuvant tamoxifen for five years (539 patients)
Number of subjects: 1070

Group type: COMPARATOR
Intervention: Tamoxifen for at least six weeks on confirmation of first recurrence (531 patients)
Number of subjects: 1070
Study: 6638906

Group type: EXPERIMENTAL
Intervention: Metronidazole (1000 mg vaginally preoperatively and 500 mg intravenously during surgery)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 112
Study: 27734127

Group type: EXPERIMENTAL
Intervention: WWCrB (Chromium-enriched yeast whole wheat bread)
Number of subjects: 30

Group type: COMPARATOR
Intervention: WWB (Plain whole wheat bread)
Number of subjects: 30
Study: 27894541

Group type: EXPERIMENTAL
Intervention: AcceleDent Aura appliance
Number of subjects: 40
Study: 23765182

Group type: EXPERIMENTAL
Intervention: Advisor Teller Money Manager (ATM) money management intervention
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 90
Study: 22431675

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 800 IU/d
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) 600 IU/d (predicted)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Vitamin D(3) (various doses)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 20977851

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 73

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 73
Study: 18240113

Group type: EXPERIMENTAL
Intervention: Schema-focused Emotive Behavioural Therapy (SET)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 93
Study: 16396443

Group type: EXPERIMENTAL
Intervention: Genetic susceptibility testing for Alzheimer's disease
Number of subjects: 60
Study: 12610049

Group type: EXPERIMENTAL
Intervention: 1.25 mg/day ramipril
Number of subjects: 4912

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4912
Study: 9456256

Group type: EXPERIMENTAL
Intervention: Daily filgrastim (1 microg/kg daily, adjusted up to 10 microg/kg daily)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Intermittent filgrastim (300 microg daily one to three times per week to a maximum of 600 microg daily)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (filgrastim if severe neutropenia developed)
Number of subjects: 258

Group type: EXPERIMENTAL
Intervention: Filgrastim-treated patients
Number of subjects: 258
Study: 8903614

Group type: EXPERIMENTAL
Intervention: Adrenalectomized subjects
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy age‐matched normotensive controls
Number of subjects: 20
Study: 2404346

Group type: EXPERIMENTAL
Intervention: Flunarizine (10 mg at night)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Propranolol (60 mg 3 times a day)
Number of subjects: 58
Study: 713957

Group type: EXPERIMENTAL
Intervention: Biarison (900 mg to 1500 mg/day)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 31067745

Group type: EXPERIMENTAL
Intervention: Vitamin D3 gummies (20,000 IU)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Vitamin D3 tablets (20,000 IU)
Number of subjects: 31
Study: 27068367

Group type: EXPERIMENTAL
Intervention: Experimental group (self-administered action observation treatment)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (nature video)
Number of subjects: 31
Study: 25449310

Group type: EXPERIMENTAL
Intervention: Acupuncture at P6 point before chemotherapy infusion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Ondansetron 8 mg intravenously 30 min before chemotherapy infusion
Number of subjects: 70
Study: 22952304

Group type: EXPERIMENTAL
Intervention: Constraint-induced therapy
Number of subjects: 47

Group type: COMPARATOR
Intervention: Traditional rehabilitation
Number of subjects: 47
Study: 19190563

Group type: EXPERIMENTAL
Intervention: 200 mL carbohydrate drink 2 hours before surgery
Number of subjects: 123

Group type: COMPARATOR
Intervention: Nil per os after midnight (control group)
Number of subjects: 123
Study: 19471137

Group type: COMPARATOR
Intervention: 40-minute exercise sessions (n = 198)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: 60-minute exercise sessions (n = 219)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Patients with acute myocardial infarction and/or coronary artery bypass graft surgery
Number of subjects: 417
Study: 17237664

Group type: EXPERIMENTAL
Intervention: Lacosamide (100 to 400 mg/d or maximum tolerated dose)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Lacosamide
Number of subjects: 119
Study: 15478383

Group type: EXPERIMENTAL
Intervention: Omalizumab treatment
Number of subjects: 19
Study: 11466696

Group type: EXPERIMENTAL
Intervention: Mylotarg (gemtuzumab ozogamicin) therapy
Number of subjects: 119
Study: 9466172

Group type: EXPERIMENTAL
Intervention: Moclobemide (450 mg/day, range 300-600 mg/day)
Number of subjects: 624

Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day, range 10-30 mg/day)
Number of subjects: 624

Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 624

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study: 7737072

Group type: EXPERIMENTAL
Intervention: Standard treatment plus 2 months use of the tape player
Number of subjects: 41

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Combined treatment (both groups)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Use of the device
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Provision of devices
Number of subjects: 41
Study: 2191018

Group type: EXPERIMENTAL
Intervention: Isoflurane sedation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam sedation
Number of subjects: 60
Study: 226306

Group type: EXPERIMENTAL
Intervention: estradiol vaginal cream
Number of subjects: 29

Group type: COMPARATOR
Intervention: conjugated estrogen cream
Number of subjects: 29
Study: 31471527

Group type: EXPERIMENTAL
Intervention: Stent Retriever (SR)
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Contact Aspiration (CA)
Number of subjects: 336

Group type: COMPARATOR
Intervention: FPE patients (SR and CA combined)
Number of subjects: 336

Group type: COMPARATOR
Intervention: Non-FPE patients
Number of subjects: 336
Study: 31129279

Group type: EXPERIMENTAL
Intervention: Multiple arterial phase imaging (DISCO)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Single arterial phase imaging
Number of subjects: 132
Study: 27495262

Group type: EXPERIMENTAL
Intervention: Argus II retinal prosthesis system ON
Number of subjects: 28

Group type: COMPARATOR
Intervention: Argus II retinal prosthesis system OFF
Number of subjects: 28
Study: 24628553

Group type: EXPERIMENTAL
Intervention: Pro+CHO (20 g intrinsically L-[1-(13)C]-phenylalanine-labeled protein with 60 g carbohydrate)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pro (20 g intrinsically L-[1-(13)C]-phenylalanine-labeled protein without carbohydrate)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pro+CHO
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pro
Number of subjects: 49
Study: 22952178

Group type: EXPERIMENTAL
Intervention: Leucine intake of >500 mg · kg⁻¹ · d⁻¹
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Leucine intake of 500 mg · kg⁻¹ · d⁻¹
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Leucine intake of 750 mg · kg⁻¹ · d⁻¹
Number of subjects: 5
Study: 20723631

Group type: EXPERIMENTAL
Intervention: Pneumococcal polysaccharide vaccine (PPV)
Number of subjects: 786

Group type: COMPARATOR
Intervention: Non-PPV group
Number of subjects: 786
Study: 18275575

Group type: EXPERIMENTAL
Intervention: Celecoxib 200 mg orally 12 hourly for 24 hours
Number of subjects: 329

Group type: COMPARATOR
Intervention: Diclofenac 100 mg orally 12 hourly for 24 hours
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 329

Group type: COMPARATOR
Intervention: Diclofenac
Number of subjects: 329
Study: 15891564

Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus vaccination
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Measles-mumps-rubella vaccination
Number of subjects: 37

Group type: COMPARATOR
Intervention: Maintenance chemotherapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Cessation of therapy (3-6 months)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 37
Study: 12504699

Group type: EXPERIMENTAL
Intervention: Intacs microthin prescription inserts
Number of subjects: 26
Study: 10800872

Group type: EXPERIMENTAL
Intervention: ZDV 100 mg tid + 200 mg nocte (ZDV-A)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: ZDV 250 mg bid (ZDV-B)
Number of subjects: 204

Group type: COMPARATOR
Intervention: ZDV-A and ZDV-B
Number of subjects: 204
Study: 8822458

Group type: EXPERIMENTAL
Intervention: MTX dissolved in saline solution (solution group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: MTX suspensions (suspension group)
Number of subjects: 26
Study: 2250925

Group type: EXPERIMENTAL
Intervention: Self-instructional booklet on pain control techniques (experimental group)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Self-instructional booklet on citizenship (placebo group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group waited quietly for 13 min
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Warning periods of 5, 30, 60, and 180 sec
Number of subjects: 36
Study: 6986940

Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of morphine sulphate (3.5 times the pain-relieving dose, mean 36 mg)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intramuscular morphine sulphate (pain-relieving dose, mean 110 mg) administered four-hourly for the first 24 hours, six-hourly for the next 24 hours, and then eight and 20 hours later
Number of subjects: 45

Group type: COMPARATOR
Intervention: Intramuscular morphine sulphate (pain-relieving dose, mean 140 mg) as required
Number of subjects: 45
Study: 29490082

Group type: EXPERIMENTAL
Intervention: Participant-interventionist bond at 4 weeks
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: Adherence (session attendance and online self-monitoring diary completion) at 6 months
Number of subjects: 398

Group type: EXPERIMENTAL
Intervention: WAI-Bond subscale
Number of subjects: 398
Study: 28146063

Group type: EXPERIMENTAL
Intervention: Two eggs per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oatmeal breakfast
Number of subjects: 50
Study: 26076964

Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc score
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: CHADS2 score
Number of subjects: 2010

Group type: EXPERIMENTAL
Intervention: CHA2DS2‐VASc and CHADS2 scores
Number of subjects: 2010
Study: 23800784

Group type: EXPERIMENTAL
Intervention: peg-interferon α‐2a at 180 μg/week
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control (observation)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: peg-interferon α‐2a
Number of subjects: 52
Study: 21297523

Group type: EXPERIMENTAL
Intervention: GH 33 μg/kg/d
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: GH 67 μg/kg/d
Number of subjects: 147

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 147
Study: 19031282

Group type: EXPERIMENTAL
Intervention: HPV 16/18 vaccination
Number of subjects: 710
Study: 17311807

Group type: EXPERIMENTAL
Intervention: Hypoxic exposure (10-15% O2)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Normoxic exposure (21% O2)
Number of subjects: 10
Study: 15557357

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy
Number of subjects: 724

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (100 operations/year, reusable trocars)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (50 operations/year, disposable trocars)
Number of subjects: 724

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy
Number of subjects: 724
Study: 11158001

Group type: EXPERIMENTAL
Intervention: PTH infusion (0.55 U/kg.h for 24 h) before GnRH agonist therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PTH infusion (0.55 U/kg.h for 24 h) after 6 months of GnRH agonist therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: PTH infusion (0.55 U/kg.h for 24 h)
Number of subjects: 11
Study: 9663722

Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg b.d.)
Number of subjects: 356

Group type: COMPARATOR
Intervention: Omeprazole (20 mg b.d.)
Number of subjects: 356
Study: 7840513

Group type: EXPERIMENTAL
Intervention: Abrasio only (follow-up for 2 years)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Abrasio only (follow-up for 5 years)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Abrasio only (for patients with very severe atypia)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Abrasio only (for another group of patients with atypical hyperplasia)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Abrasio only (for other patients)
Number of subjects: 368
Study: 3223435

Group type: COMPARATOR
Intervention: Ethanol (doses ranging from 0 to 1.05 g/kg lean body weight)
Number of subjects: 0
Study: 29343448

Group type: EXPERIMENTAL
Intervention: 300‐mg ropivacain/600‐300‐300‐mg gabapentin (Group A)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 150‐mg ropivacain/600‐300‐300‐mg gabapentin (Group B)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 300‐mg ropivacain/300‐100‐100‐mg gabapentin (Group C)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: 150‐mg ropivacain/300‐100‐100‐mg gabapentin (Group D)
Number of subjects: 128
Study: 27473584

Group type: EXPERIMENTAL
Intervention: Interactive film-based sexual-health intervention entitled If I Were Jack
Number of subjects: 800